Strong cash flow and significant actions to improve profitability within Medtechcomments by the ceo
Demand is high in the markets and segments where AddLife's companies operate. We can now summarize 2023 as a year with historically strong organic growth of 10%. In the fourth quarter, cash flow improved significantly and net debt decreased by approximately SEK 400 million.
Year-end report 2023Video conference
Investors, analysts and the media are invited to a video conference where CEO Fredrik Dalborg and CFO Christina Rubenhag will present the year-end-report. The presentation will be held in English and takes about 20 minutes, after which there will be an opportunity to ask questions. It will be recorded and made available online.
The report is released Friday, February 2, 2024 at 07.45 a.m
Video conference at 9:00 a.m
AddLife creates value
The laboratory and medical technology market is relatively insensitive to economic fluctuations. Growth tends to be stable and is mainly driven by population growth and an ageing population. These trends increase the demand for AddLife's healthcare and research products. Historically, the markets where we operate have grown at an annual rate of 2-4 percent.
AddLife’s subsidiaries are strongly cash generative, which gives financial opportunity for acquisitions and investments.
AddLife has substantial experience of acquisitions, identifying candidates and completing successful transactions.
AddLife’s subsidiaries have strong sales organisations with high technological expertise and long term customer relationships.
Target fulfilment 2022
The investor pages contain all published financial information to facilitate investment decisions.
We are happy to assist you in understanding our business and financial results. Please do not hesitate to contact us if you would like more information, or if you have any suggestions for improving our service.
IR- and press contacts
Your subscription is now saved and you will receive an email to verify your email address and activate the subscription.